The approval is based on Phase 3 EPIDYS trial data that demonstrated meaningful treatment benefits in ambulant patients MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the ...

Dutch government collapse: What has happened and what will the implications be? 11 Expensive Steakhouse Chains That Aren't Worth The Price Tag Miley Cyrus Sets The Record Straight On Her ...

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy. Leukemia, 2025; DOI: 10.1038/s41375-025-02584-9 ...

The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene.

Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial By James Waldron Sep 30, 2024 9:35am pulmonary arterial hypertension HDAC hypertension clinical trial data ...

Email: [email protected] Keywords: decitabine, HDAC inhibitors, pancreatic cancer, PARP inhibitors, synergistic cytotoxicity Click here to sign up for freeAltmetric alerts about this article.

Background: Relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) has a poor prognosis. Double-expressor (DEL) or TP53 abnormal r/r DLBCL patients (pts) are associated with even worse outcomes ...

The MSSM researchers believe that their findings could lead to new kinds of HDAC inhibitors for treating some types of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease ...

More work is needed to pinpoint how to best deliver HDAC inhibitors to the dense fibrotic tissue around pancreatic tumors, as well as how they might be most effectively combined with other cancer ...

If you have more HDAC activities in the fibroblasts, you have a worse outcome. On the other hand, if you inhibit the HDACs, you have a better outcome.” ...

Now, new findings in mice suggest that homing in on one HDAC in particular may have therapeutic potential against a currently untreatable form of non-small cell lung cancer, or NSCLC.

Background: Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase (HDAC) inhibitor with demonstrated efficacy and safety in combination with exemestane in ...